Gilead Sciences (GILD) Tops Q1 EPS by 31c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Gilead Sciences Announces First Quarter 2022 Financial Results
April 28, 2022 4:02 PM EDTBiktarvy Sales Increased 18% Year-Over-Year to $2.2 billion
Oncology Sales Increased 60% Year-Over-Year to $420 million
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter of 2022.
Gileads performance in the first quarter reflects the strength and diversity of our business with both our HIV and oncology therapies contributing to year-over-year growth, said Daniel ODay, Chairman and Chief Executive Officer, Gilead Sciences. Biktarvy delivered strong 18% year-over-year revenue growth, and oncology sales increased by 60% year-over-year,... More
